Free Trial
NASDAQ:KLDO

Kaleido Biosciences (KLDO) Stock Price, News & Analysis

Kaleido Biosciences logo
$0.0050 0.00 (0.00%)
As of 04/24/2025

About Kaleido Biosciences Stock (NASDAQ:KLDO)

Key Stats

Today's Range
$0.0050
$0.0050
50-Day Range
N/A
52-Week Range
$0.00
$0.25
Volume
N/A
Average Volume
10,430 shs
Market Capitalization
$213,115.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

Kaleido Biosciences Inc (KLDO)
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Kaleido Biosciences (OTC: KLDO)
See More Headlines

KLDO Stock Analysis - Frequently Asked Questions

Kaleido Biosciences' stock was trading at $0.0001 at the beginning of 2025. Since then, KLDO stock has increased by 4,900.0% and is now trading at $0.0050.
View the best growth stocks for 2025 here
.

Kaleido Biosciences, Inc. (NASDAQ:KLDO) posted its quarterly earnings results on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The company earned $0.10 million during the quarter, compared to the consensus estimate of $0.25 million.

Kaleido Biosciences (KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kaleido Biosciences investors own include Editas Medicine (EDIT), Enovix (ENVX), COMPASS Pathways (CMPS), Rambus (RMBS), Luminar Technologies (LAZR), Precision BioSciences (DTIL) and Globant (GLOB).

Company Calendar

Last Earnings
11/01/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Computer Software
Current Symbol
NASDAQ:KLDO
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
38,787,000
Market Cap
$213,115.00
Optionable
Not Optionable
Beta
-0.06
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:KLDO) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners